Biopharma CI is not just delayed.
It’s miscalibrated.
It’s measuring the wrong signals, asking the wrong questions, trusting the wrong voices.
Yes, it is uncomfortable to hear this from a consultant.
The real discomfort is that it already feels true.
This keynote is not a presentation.
It is a classified debrief on the failure points your team won’t see—until it’s too late:
• How “coverage” became the enemy of consequence
• How AI fluency produces coherence without truth
• How HUMINT grids now shape strategy before advisory boards convene
• Why velocity has replaced vigilance—and no one noticed
After this session, you will not look at CI the same way.
If you do, that’s the most dangerous signal of all.

While many of these headwinds are daunting, CI professionals are uniquely positioned to help their organizations anticipate market shifts, decode competitor strategy, and proactively mitigate risk. This session will explore the most critical industry challenges and offer actionable recommendations on how CI teams can deliver strategic value.

The US is unarguably the largest market in the world both from a financial and activity , and is therefore understandably the focus of our collective efforts. Within the CI industry we will often give extra attention to preclinical studies emerging from well-funded and well-publicised US academic institutions or companies, published in US journals, and will use the US-centric clinicaltrials.gov as the core of our pipeline asset monitoring activities, and all predictions which result from it. And yet, most estimations show that the US market represents less than half of the global market and so we ask whether we are doing a disservice to most of our customers by giving overweight focus to the US market? In this study we will reflect on decades of collective work with global, regional and country teams to identify areas of global programs which we believe do offer value to European country teams, and those that don’t. We will offer our thoughts on how to use a global or regional view as a core knowledge-base which can allow efficient tactical research into focussed topics to deliver relevant insights which can be value drivers for country teams in the region. In a case study we will suggest that collaboration and agility are critical parameters to build into a CI program which delivers to European teams.

• Key elements of an excellent CI narrative with a clearly-articulated storyline, including how to win confidence as a narrator
• How a CI narrative with a clearly-articulated storyline elevates the value of CI by boosting engagement, comfort, connection, alignment and contribution
• How great storytelling “moves the needle” on critical objectives and amplifies strategic messages
• How to control your CI storyline across multi-functional stakeholders
• How to best use AI as part of this process

The CLIN platform provides analysis from curated oncologist commentary across social media, tracking sentiment, surfacing key conference signals, and benchmarking evolving standards of care. Combining social, scientific, and commercial data supports timely pharma decision-making.

Agentic AI changes this dynamic. It empowers AI agents to autonomously recognize meaningful patterns, proactively uncover insights, and even recommend or execute strategic actions, all within predefined goals and guardrails established by human decision-makers.

In this engaging session, David Seuss, founder and CEO of Northern Light, will share practical examples of how Agentic AI is reshaping market research and competitive intelligence in pharma, empowering organizations to move beyond reacting to market changes toward actively driving strategic decisions. Mr. Seuss will illustrate how Agentic AI:

• Accelerates strategic responses to rapidly shifting market conditions.
• Enables highly personalized insights at scale.
• Streamlines competitive intelligence through autonomous monitoring and analysis of market dynamics.

However, the development and commercialization of biosimilars differ substantially from that of generic NMEs. As a result, modern biosimilar manufacturers must stay attuned to key market trends, technological advancements, shifting dynamics, and global collaborations.
This session will shed light on the tailored competitive intelligence (CI) needs of biosimilar companies and how they diverge from traditional approaches used in innovative drug development market monitoring. It aims to help biosimilar manufacturers reassess their essential CI requirements and build a compelling case for securing the necessary budget from leadership teams.

As access to information became easier and information flow increased, CI departments have shifted their focus to “so what” – why is this new competitive information relevant to my company, focusing on insights rather than data gathering. We expect this trend to continue to evolve, from “what” to “so what” to “now what.” CI professionals need to go beyond implications to strategy recommendations. Our panel will discuss best practices for embedding strategic recommendations in all of your CI deliverables.

The issues with supply-demand imbalance, inflation, market volatility and geopolitical tensions & conflicts continue to pose a degree of instability and challenges for economic recovery and growth prospects. Although the pharmaceutical industry is often viewed as recession-proof, it is not immune to future challenges. Ongoing drug pricing and reimbursement constraints, regulatory challenges, pressures to innovate, increased competition, as well as biotech funding instability will continue to test the biopharmaceutical industry in the coming years.
In The State of the Biopharmaceutical Industry discussion, GlobalData will highlight what we see are the factors impacting business environment and key trends that are going to shape the biopharmaceutical industry in 2025 and beyond.

• Regional share of total number of oncology trials and associated evolution from 2019 to 2024
• Spotlight on Europe; heat map of clinical trial growth verses a 2019 baseline – the Covid impact
• Illustrative country comparison; UK verses Romania
Analysis of data that is easily accessible that can help pharma business units and therapy area teams gain a competitive edge by conducting trials in geographies that others aren’t

This talk is to explore how CI is being repositioned as a strategic business partner driving value across the enterprise.
Objective
To provide attendees with:
• Real-world insights on how CI teams are embedding themselves into strategic decision-making
• Practical takeaways on evolving CI capabilities, processes, and influence
• Perspectives from cross-functional stakeholders on what they value most in CI as a partner
• A vision for future-proofing CI—adapting to AI, data integration, and strategic foresight needs

TRENDS: combination products to address side effects (muscle loss) & exciting new indications (MASH, addiction, etc); non Peptide GLP1s; the rise of China as a producer & innovator; new delivery systems
CHALLENGES: supply chain; manufacturing inefficiencies; geopolitics; market access; how to differentiate your GLP1.
OPPORTUNITIES: differentiation by combo products; development of new non Peptide GLP1 drug substances; drug delivery innovation; companion products in the medical device, food, nutrition, lifestyle space

This session explores how primary CI—grounded in direct, real-world insight—can inform timely course correction, future-proof decision-making, and sharpen competitive advantage across the product lifecycle from early stage evaluation to late life cycle management. What’s in it for you? Attendees will gain practical understanding of how to integrate primary CI into strategic execution and how deeper insights and how a four-pronged methodology translates to measurable impact leading to strategic advantage.

Salvador Carlucci, whose landmark 2005 Nature Biotechnology articles reshaped how biotech approached competitive intelligence, unveils the dramatic evolution of CI in the age of artificial intelligence. This provocative session bridges his original framework with cutting-edge AI capabilities, revealing unexpected synergies and disruptive opportunities. Discover how today’s most forward-thinking pharma companies are supercharging their CI methodology—from intelligence gathering to strategic decision-making—through sophisticated Agentic AI integration.

This session explores how CI teams can overcome these challenges by integrating and harmonizing critical datasets for a more holistic, real-time view of the competitive landscape. We’ll discuss best practices for reducing manual effort, leveraging purpose-built visualizations, and streamlining report generation to elevate strategic intelligence. Attendees will gain practical takeaways on how enhanced CI workflows can lead to sharper insights, faster response times, and more confident decision-making.